Investor Presentaiton

Significant Opportunity in Molecular Diagnostics BEST-IN-CLASS MOLECULAR DX OFFERING Cepheid. ANNUAL REVENUE & GLOBAL INSTALLED BASE ~50K • Differentiated position at critical, point-of-care settings >$4.5B >40K • Workflow + speed + accuracy • Broadest test menu: >35 OUS, >20 in the US ~$3.5B >30K ~$2B >20K Cepheid GeneXpertⓇ >10K Systems & ~$1B test cartridge GeneXpert XXpress SARS-COPY $0.6B 2016 (At 2019 2020 2021 2022 Acq.) RESULTS SINCE 2019: >2X INCREASE IN INSTALLED BASE >4X REVENUE INCREASE 22 22 DANAHER Cepheid uniquely positioned for long-term growth opportunity

View entire presentation